Depo-Provera Settlement Amounts: A Deal Exists, the Terms Do Not
In June 2026 Pfizer told investors it had reached an agreement-in-principle with plaintiff leadership that it expects to resolve a substantial majority of the pending MDL cases. It disclosed no amount, recorded no separate reserve, and described the terms as not material to the company’s liquidity or financial condition. That is the entire public record on Depo-Provera settlement amounts.
Where the Depo-Provera Litigation Actually Stands
This docket moved faster than most. It went from creation to an agreement-in-principle in about sixteen months, which is unusual and worth understanding.
A French national case-control study covering 18,061 women who underwent intracranial surgery for meningioma between 2009 and 2018, matched to 90,305 controls, reported an odds ratio of 5.55 for prolonged use of injectable medroxyprogesterone acetate. The same study found no excess risk for levonorgestrel intrauterine systems or oral progesterone.
Pfizer’s own filing records that the federal Depo-Provera cases were transferred for coordinated pre-trial proceedings to an MDL in the Northern District of Florida, before Judge M. Casey Rodgers. The named defendants include Pfizer, Pharmacia and Upjohn, Pharmacia LLC, Greenstone, Viatris and Prasco.
Coordinated proceedings were established in several state jurisdictions including California, Connecticut, Delaware and New York. A Depo-Provera claim filed in one of those states may not be inside the federal MDL at all, which matters for whether any federal resolution reaches it.
The approved Depo-Provera CI prescribing information was revised to add meningioma to Warnings and Precautions at section 5.4, stating that cases of meningiomas have been reported following repeated administration of medroxyprogesterone acetate, primarily with long term use, and instructing prescribers to monitor for signs and symptoms and to discontinue the drug if a meningioma is diagnosed.
Pfizer told investors it had reached an agreement-in-principle with plaintiff leadership that it expects to resolve a substantial majority of the pending MDL cases, on terms that are not material to the company’s liquidity or financial condition. No amount was disclosed and no separate reserve was reported.
The JPML report published that morning shows 6,403 actions pending in MDL 3140 out of 6,510 filed. No settlement terms had been filed publicly and no claims administrator had been announced.
Confirmed Depo-Provera Facts vs. TortAdvisor Editorial Estimates
This page has more confirmed science and more confirmed procedure than most, and less confirmed money than almost any. Keeping the columns apart matters.
Confirmed public facts
- MDL 3140 exists. Federal cases were centralised in February 2025 before Judge M. Casey Rodgers in the Northern District of Florida, with 6,403 pending of 6,510 filed.
- Pfizer disclosed an agreement-in-principle in June 2026 expected to resolve a substantial majority of the pending MDL cases.
- Pfizer described the terms as not material to its liquidity or financial condition, and disclosed no amount.
- The FDA label was revised in December 2025 to add meningioma to Warnings and Precautions with monitoring and discontinuation instructions.
- The BMJ reported an odds ratio of 5.55 for prolonged injectable medroxyprogesterone acetate use, in a study of 18,061 surgical meningioma cases.
- Coordinated state proceedings exist in California, Connecticut, Delaware and New York alongside the federal MDL.
Not established, whatever you have read
- The settlement total. Pfizer disclosed no figure and recorded no separate reserve.
- The per-claim allocation. No matrix, no tiers and no administrator have been published.
- Which claims are inside the deal. “A substantial majority” leaves an unquantified remainder outside it.
- Whether the coordinated state cases are covered. Pfizer’s disclosure addresses the MDL cases.
- When money would actually move. No claims process has been announced.
Depo-Provera Claim Profiles, Without Invented Figures
We publish no dollar range for a Depo-Provera claim, because the settlement terms have not been made public. What follows describes how these claims differ from one another. The profiles carry no figures on purpose.
Resected meningioma with lasting deficit
- Craniotomy with pathology confirming meningioma
- Permanent neurological effects: seizures, vision or hearing loss, cognitive change
- Many years of documented Depo-Provera injections
- Radiotherapy or repeat surgery for recurrence
- Substantial economic loss and continuing care
Surgically treated with recovery
- Tumour resected, good functional outcome
- Documented injection history over a meaningful period
- Ongoing surveillance imaging
- Some lasting effects but no major permanent deficit
Diagnosed but observed
- Meningioma identified on imaging and managed by monitoring
- No surgery, so no operative or pathology record
- Shorter or less well documented injection history
- A materially thinner evidentiary picture than the profiles above
What Will Happen Between a Gross Depo-Provera Recovery and a Deposit
With an aggregate resolution in prospect, this is the sequence that will determine what a household actually receives.
Allocation
In an aggregate settlement each claim is assigned an amount, usually by a matrix weighing duration of use, tumour treatment and severity. That matrix has not been published here.
Fees and costs
The contingency fee and case expenses come out under the fee agreement, plus any common-benefit assessment the MDL court orders on cases that used the shared work product.
Liens
Neurosurgery and follow-up imaging are expensive and almost always billed to an insurer. Medicare, Medicaid and private plans assert reimbursement rights that must be resolved first.
Net to the claimant
What remains is what reaches the household. In an aggregate settlement with an undisclosed total, this is the number nobody can estimate honestly in advance.
Participation thresholds are worth asking about. Aggregate pharmaceutical settlements frequently require a high percentage of eligible claimants to opt in before the defendant is bound. Whether one applies here has not been made public.
How TortAdvisor Compiles This Depo-Provera Page
The method is deliberately narrow, and on a docket with an undisclosed settlement it mostly consists of refusing to guess the number.
Controlling court first
Orders from Judge Rodgers’ court outrank every summary of them, including ours.
Then the JPML
Case counts come from the Panel’s own monthly report, never from a site that rounds them up.
Then SEC filings
Settlement facts are used only where the defendant disclosed them to the SEC, where misstating them carries consequences.
Then label and peer review
The FDA-approved label for the regulatory position, and the published study itself for the science.
The Depo-Provera Science, Stated Precisely
Because there is no published settlement figure to tabulate, the honest thing to put here is the evidence and the regulatory record the litigation rests on, with their real numbers and their real limits.
| Source | What it covered | Finding | Stated limitation |
|---|---|---|---|
| BMJ, 2024 | French national case-control study: 18,061 women who had intracranial surgery for meningioma, 2009 to 2018, and 90,305 matched controls | Prolonged use of injectable medroxyprogesterone acetate carried an odds ratio of 5.55 | The 95 percent confidence interval runs from 2.27 to 13.56, which is wide. The estimate is real but imprecise. |
| The same study, other progestogens | Levonorgestrel intrauterine systems, oral and vaginal progesterone, dydrogesterone | No excess meningioma risk found for any of them | This strengthens the specificity of the injectable finding rather than weakening it. |
| FDA-approved label, revised 12/2025 | Depo-Provera CI prescribing information | Meningioma added to Warnings and Precautions, with instructions to monitor and to discontinue if diagnosed | A label warning is a regulatory judgement about a population. It is not a finding that any individual tumour was caused by the drug. |
| Pfizer Form 10-Q, filed Aug. 4, 2026 | Contingencies note covering the meningioma litigation | Agreement-in-principle reached June 2026, expected to resolve a substantial majority of pending MDL cases | Terms described as not material to Pfizer’s liquidity or financial condition. No amount and no separate reserve disclosed. |
The study measured surgery, not diagnosis. The BMJ cases were women who underwent intracranial surgery for meningioma, so the finding is anchored in surgically treated tumours. A Depo-Provera claim built on a meningioma that was found on imaging and left under observation sits on a different evidentiary footing, which is one reason the claim profiles above separate them.
Who May Have a Depo-Provera Claim
These are the criteria the litigation has organised itself around, not a promise that any claim will be accepted, included in the settlement or paid.
Commonly present in these claims
- A diagnosis of meningioma, confirmed by imaging and, where surgery followed, by pathology
- A documented history of Depo-Provera or generic depot medroxyprogesterone acetate injections
- Prolonged use, which is the pattern the published research associates with elevated risk
- Injections that preceded the diagnosis by a plausible interval
- Pharmacy or clinic records that prove the injections were actually given
- A claim brought within the limitation period the relevant state applies
What weakens or complicates a claim
- No record of the injections, which is the most common problem in this litigation
- A small number of injections over a short period
- A brain tumour that is not a meningioma, which is a different claim entirely
- A tumour diagnosed before or shortly after the injections began
- A limitation period that has already run under the applicable state rule
Eligibility is a legal question that depends on the records and the law of the state involved, and only an attorney reviewing the actual file can answer it, including whether a particular claim falls inside the group Pfizer’s agreement-in-principle covers. Our Depo-Provera lawsuit guide covers the claims and defendants in more detail, and the Depo-Provera settlement calculator organises these factors without deciding any of them.
What Moves the Value of a Depo-Provera Claim
These are the differences an allocation matrix in this litigation would be built on. None of them produces a number while the terms remain unpublished.
Duration of use
The published research associates the risk with prolonged use, so how many years of documented injections a Depo-Provera claim can prove is the fact that carries most weight.
Proof of the injections
Pharmacy dispensing records and clinic administration notes naming the product and the dates. Recollection alone is a materially weaker claim than a paper trail.
Whether surgery was needed
A resected tumour produces an operative report and a pathology diagnosis. A tumour under observation produces neither, and the research itself was built on surgical cases.
Neurological outcome
Seizures, vision or hearing loss, cognitive effects, hormone disturbance and any permanent deficit after treatment. This is the damages half of the analysis.
Timing
Whether the injections preceded the diagnosis by an interval that makes biological sense, and how the dates sit against the limitation rule that applies.
Which court the claim is in
Federal MDL or one of the coordinated state proceedings. Pfizer’s disclosed agreement addresses the MDL cases, which makes this distinction unusually consequential here.
The Records a Depo-Provera Claim Is Built From
Two proofs are needed: that you had the injections, and that you had the tumour. The first is the one that goes missing.
Injection records
Pharmacy dispensing histories and clinic administration notes showing each injection and its date. This is the foundation of a Depo-Provera claim and the hardest part to reconstruct.
Duration of use
How many years the injections continued, and whether there were gaps. Prolonged use is what the research associates with elevated risk, so the timeline matters as much as the fact.
Imaging
The MRI or CT report identifying the meningioma, with size and location, plus the images themselves where they can still be obtained.
Neurosurgical and pathology reports
Operative notes, the extent of resection and pathology confirming the tumour type and grade. Where surgery happened, this is the strongest documentation in the file.
Treatment and outcome
Radiotherapy, follow-up imaging, seizure history, neurological examinations and any documented permanent deficit.
Damages documentation
Medical bills, insurance statements, lost earnings and the cost of continuing surveillance and care.
Start with the pharmacy, not the hospital. Hospital and imaging records are usually retrievable for a long time. Injection records held by a clinic that has since closed, merged or changed systems are the ones that disappear, and without them a Depo-Provera claim has no exposure proof.
Deadlines in a Depo-Provera Claim
Timing is unusually live on this docket, because a settlement in principle can bring its own participation deadlines that have nothing to do with a statute of limitations.
Why time may still be available
- Most states run the clock from diagnosis, or from when the link between the drug and the tumour was reasonably discoverable
- The FDA label warning was only added in December 2025, which is relevant to when the connection became reasonably knowable
- The MDL remains open and continued to receive filings through 2026
- An agreement-in-principle is not a closed door; terms and participation windows had not been published as of September 2026
Why time may already have run
- Limitation periods are commonly two or three years and vary substantially by state
- Wrongful death claims usually run from the date of death and are frequently shorter
- Some states impose a statute of repose that can cut off a claim regardless of discovery
- Settlement participation deadlines, once set, are typically short and strictly enforced
Take the Depo-Provera Settlement Calculator Below
The calculator organises what you know about the injections, the diagnosis, the treatment and the financial loss, then shows which factors carry the most weight in a Depo-Provera claim. It takes a few minutes and asks for no documents.
The result is educational and is not a guaranteed case value or settlement offer.
Before You Start
- Roughly when the injections started and stopped
- About how many years they continued
- When the meningioma was diagnosed
- Whether surgery or radiotherapy followed
- Any lasting neurological effects and ongoing care
Primary Sources for This Page
Every figure above traces to one of these. We link them so you can check the page rather than trust it.
Pfizer Form 10-Q contingencies note
Pfizer’s own disclosure of the June 2026 agreement-in-principle with plaintiff leadership, expected to resolve a substantial majority of the pending MDL cases on terms not material to the company’s liquidity or financial condition, together with the February 2025 MDL transfer and the coordinated state proceedings. Read the note on EDGAR
JPML transfer order in MDL 3140
The Panel order in In re Depo-Provera (Depot Medroxyprogesterone Acetate) Products Liability Litigation, naming Judge M. Casey Rodgers of the Northern District of Florida, the defendants and the common factual questions. Read the transfer order (PDF)
JPML pending MDL report
The Panel’s monthly statistics, the source of the 6,403 pending and 6,510 total figures for MDL 3140. See the pending MDL statistics
FDA-approved Depo-Provera CI label
The prescribing information revised 12/2025, adding meningioma to Warnings and Precautions at section 5.4 and instructing prescribers to monitor for signs and symptoms and to discontinue if a meningioma is diagnosed. Read the label (PDF)
BMJ, 2024
Roland N, Neumann A, Hoisnard L, et al. Use of progestogens and the risk of intracranial meningioma: national case-control study. BMJ 2024;384:e078078. The study behind this litigation, with the odds ratio of 5.55 for prolonged injectable medroxyprogesterone acetate use and the null findings for levonorgestrel intrauterine systems and oral progesterone. Read the study
FDA supplement approval letter
The FDA approval letter for the label supplements that carried the meningioma warning into the approved prescribing information. Read the approval letter (PDF)
Questions People Ask
How much is the Depo-Provera settlement?
Pfizer has not said. Its August 2026 filing discloses an agreement-in-principle reached in June 2026 and describes the terms as not material to the company’s liquidity or financial condition, but gives no total, no per-claim figure and no reserve. Any Depo-Provera settlement amount quoted elsewhere is somebody’s guess.
Does “not material” mean the settlement is small?
It means small relative to Pfizer, which is a company whose quarterly revenue runs into the tens of billions. A sum that is immaterial on that scale could still be substantial spread across several thousand claims, or it could be modest. The phrase loosely limits the ceiling and says nothing about the floor.
Is my claim included in the settlement?
Nobody can tell you that from a web page. Pfizer’s disclosure refers to a substantial majority of the pending MDL cases, which leaves an unquantified remainder outside it, and it addresses the federal MDL rather than the coordinated state proceedings in California, Connecticut, Delaware and New York. Your own attorney is the only person who can answer this.
What does the research actually show?
A 2024 BMJ national case-control study of 18,061 women who had intracranial surgery for meningioma found an odds ratio of 5.55 for prolonged use of injectable medroxyprogesterone acetate. The confidence interval runs from 2.27 to 13.56, which is wide, so the association is clear but the magnitude is imprecisely estimated. The same study found no excess risk for levonorgestrel intrauterine systems or oral progesterone.
Does the FDA warning prove causation in my case?
No. In December 2025 the approved label added meningioma to Warnings and Precautions and told prescribers to monitor for it and to discontinue the drug if one is diagnosed. That is a regulatory judgement about a population. Causation in an individual claim is proved with evidence about that claimant.
What if my meningioma was never operated on?
It is still a claim, but the evidentiary picture is thinner. The research was built on women who underwent intracranial surgery, and a resected tumour produces an operative report and a pathology diagnosis that an observed tumour does not. That difference is likely to matter in any allocation.
What if I used the generic rather than Depo-Provera?
The JPML order names Pfizer, Pharmacia and Upjohn, Pharmacia LLC, Greenstone, Viatris and Prasco as defendants, so generic depot medroxyprogesterone acetate is within the litigation. Which defendant a particular claim runs against depends on which product was actually injected, which is another reason the pharmacy record matters.
Does TortAdvisor handle Depo-Provera claims?
No. TortAdvisor is a legal research publisher. We do not represent claimants, give legal advice, accept cases or review claims, and using this page or the calculator does not create an attorney-client relationship. Our purpose is to show you what the public record says before you speak with an attorney of your own choosing.
See Which Factors May Affect a Depo-Provera Claim
Answer the questions you can about the injections, a meningioma diagnosis, treatment, records, expenses and long-term impact. The calculator organizes those inputs into an educational settlement range and highlights the factors that may matter most when a claim is reviewed.
The result is educational and is not a guaranteed case value or settlement offer.
Helpful Information to Have Ready
You do not need every record in hand. Answer what you know; these details can make the estimate more useful.
Receiving a calculator result is separate from any optional request to be contacted. Any optional consent checkbox should remain unchecked unless you affirmatively select it.
